Form 8-K - Current report:
SEC Accession No. 0001193125-26-228003
Filing Date
2026-05-18
Accepted
2026-05-18 09:01:36
Documents
12
Period of Report
2026-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d86489d8k.htm   iXBRL 8-K 38247
2 EX-2.1 d86489dex21.htm EX-2.1 15942
  Complete submission text file 0001193125-26-228003.txt   177405

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20260516.xsd EX-101.SCH 3174
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20260516_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20260516_pre.xml EX-101.PRE 11257
16 EXTRACTED XBRL INSTANCE DOCUMENT d86489d8k_htm.xml XML 3674
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 26990963
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)